Two pandemics are currently afflicting the planet. While our governments focus on the smaller one (COVID-19), the larger one (the Mental Health Crisis) is rapidly spiralling out of control.
Exploring the companies and themes that make up this emerging and exciting new sector
MINDCURE Announces Additional Equity Investment in ATMA, The First Government Approved Psychedelic Journey Centers In Canada; MCUR President and CEO, Kelsey Ramsden Named to ATMA Board of Directors
MINDCURE increases its strategic investment in ATMA Journey Centers and deploys its iSTRYM digital therapeutics platform.
Psychedelic Stocks Primed For atai-MindMed Bounce
Both the atai Life Sciences IPO and a MindMed uplisting to the NASDAQ are highly anticipated events. They could occur within weeks -- or even days -- of each other.
Hard Numbers On The Huge Potential Of Psychedelic Drug Development
Drug development is expensive. It is also EXTREMELY lucrative. We take a close look at this revenue potential.
Microdosing psychedelic drugs associated with increases in conscientiousness and reductions in neuroticism
Microdosing has become something of a wellness trend in recent years, gathering traction in Australia and overseas.
Third Massachusetts City Approves Psychedelics Decriminalization Measure
Another Massachusetts city has approved a measure to deprioritize enforcement of laws against the possession, use and distribution of a wide range of psychedelics such as psilocybin and ayahuasca.
Cashed-Up Psychedelic Stocks Well Prepared For Adverse Market Conditions
Psychedelic stocks have been hammered in recent weeks by general selling pressures on tech stocks. But with corporate coffers full, these companies can weather the storm.
Wesana Health Announces Closing of C$16.1 Million Oversubscribed Private Placement
Institutional interest in psychedelics-based TBI research increases, as Wesana closes an oversubcribed CAD$16.1 million financing.
Northampton City Council seeks to decriminalize psychedelic drugs, urge police make possession low enforcement priority
Efforts are underway to make pursuing criminal charges for possession of psychedelics less of a priority in one Western Massachusetts community.
MindMed Announces Filing of Preliminary Base Shelf Prospectus and F-10 with the SEC under MJDS
MindMed files a "Base Shelf Prospectus" with the SEC.
MINDCURE (CSE: MCUR | OTC: MCURF) Files Provisional Patent Application For iSTRYM, its Proprietary AI Digital Therapeutics (DTx) SaaS Platform, Designed To Enhance Effectiveness Of Psychedelic-Assisted Therapies For Practitioners And Patients
Company Now Is In Two High Growth Rate Global Markets With iSTRYM In The DTx Market, Projected To Reach $56 Billion By 2025 And The Global Psychedelic Market Projected To Reach Over $7.5 Billion By 20281
Why Dollar-Cost Averaging Makes Sense For Psychedelic Stocks
Psychedelic stocks have been battered by general market headwinds in recent weeks. Uncertainty could persist. How do investors allocate capital?